Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Drug development

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Introduction Monoclonal antibodies targeting amyloid-β are the first disease-modifying treatments for Alzheimer disease to have received FDA-approval. There are three different drugs approved or pending FDA-approval: aducanumab, lecanemab, and donanemab. These three drugs are each in different stages of regulatory approval by the FDA.

What this study adds

Evidence grade: Low

This is a narrative review. This paper reviews three monoclonal antibodies targeting amyloid-β—aducanumab, lecanemab and donanemab—which are the first disease-modifying treatments for Alzheimer disease to receive FDA approval or be pending it. It discusses their clinical efficacy, dosing, side effects and practical issues with using them as common treatments to slow decline.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Beveridge, J., Kaniecki, E., Naidu, A., Silverglate, B. D., & Grossberg, G. (2024). How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease? Expert opinion on emerging drugs. https://doi.org/10.1080/14728214.2024.2304059

Vancouver

Beveridge J, Kaniecki E, Naidu A, Silverglate BD, Grossberg G. How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease? Expert opinion on emerging drugs. 2024. doi:10.1080/14728214.2024.2304059. PMID: 38193477.

BibTeX

@article{beveridge2024-38193477,
  author  = {Beveridge, J. and Kaniecki, E. and Naidu, A. and Silverglate, B. D. and Grossberg, G.},
  title   = {{How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?}},
  journal = {Expert opinion on emerging drugs},
  year    = {2024},
  doi     = {10.1080/14728214.2024.2304059},
  pmid    = {38193477},
  url     = {https://doi.org/10.1080/14728214.2024.2304059}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This paper reviews three monoclonal antibodies targeting amyloid-β—aducanumab, lecanemab and donanemab—which are the first disease-modifying treatments for Alzheimer disease to receive FDA approval or be pending it. It discusses their clinical efficacy, dosing, side effects and practical issues with using them as common treatments to slow decline.

Study details

How this study scored 34/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 34 of 100.34 of 100 points earned66 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Expert opinion on emerging drugs)
Journal's citation record 0 / 4 Expert Opinion on Emerging Drugs: journal h-index 63 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 10 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.5 citations a year over 4 year(s) since 2024
Impact for its field and year 2 / 6 Cited 2.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author George Thomas Grossberg: h-index 58 (OpenAlex, whole career)
Institution's track record 0 / 3 Saint Louis University: institution h-index 567 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 38193477)
Free to read 0 / 2 Behind a paywall — scores zero
Total 34 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Drug development from nearby years

Also in Drug development

124 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.

Similar studies

More on Drug development

See all studies in Drug development →